Berkeley, CA, United States of America

Autoosa Salari

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of California. Active years: 2020.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Autoosa Salari: Innovator in Visual Function Enhancement

Introduction

Autoosa Salari is a notable inventor based in Berkeley, CA (US). He has made significant contributions to the field of visual function enhancement through his innovative research and patents. His work focuses on methods that aim to restore or enhance visual capabilities in individuals.

Latest Patents

Salari holds a patent for "Compositions and methods for enhancing visual function." This patent describes a method that involves administering a nucleic acid containing a nucleotide sequence that encodes one or more types of cone opsins. These opsins include medium wavelength cone opsin (MW-opsin), long wavelength cone opsin (LW-opsin), and short wavelength cone opsin (SW-opsin). The expression of these opsins in retinal cells is aimed at restoring or enhancing visual function in individuals.

Career Highlights

Salari is affiliated with the University of California, where he conducts his research and development. His work has garnered attention for its potential applications in improving visual health and function.

Collaborations

Some of his notable coworkers include Ehud Y Isacoff and Michael H Berry. Their collaborative efforts contribute to the advancement of research in visual function and related fields.

Conclusion

Autoosa Salari's innovative work in enhancing visual function through his patented methods represents a significant advancement in the field. His contributions have the potential to impact many individuals seeking improvements in their visual capabilities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…